- Simple preparation method of vemurafenib and analogues thereof
-
The invention provides a simple preparation method of vemurafenib and analogues thereof. The method includes: subjecting para-substituted phenylacetaldehyde II and N-[2, 4-disubstituted-3-(cyanopropionyl)phenyl]n-propanesulfonamide III to azeotropic dewatering and condensation reaction under alkaili catalysis, condensing the obtained condensation product and the methylenation reagent V(N, N-dimethylformamide or tri-orthoformate), and then performing cyclization with ammonia to obtain vemurafenib or analogues thereof. The method for preparation of vemurafenib provided by the invention has the characteristics of low cost, mild process conditions, low operation requirements, short reaction time, high production efficiency, simple process operation, little waste water production, green and environmental protection, high yield and purity, and is beneficial to green industrial production of vemurafenib. At the same time, the method provided by the invention can prepare vemurafenib analogues,and is of important significance for the drug efficacy study of similar compounds.
- -
-
-
- NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB
-
The present invention relates to novel processes for the manufacture of N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (I), wherein no protection-deprotection sequences or halogenation steps are required and the use of palladium catalysts is minimized. Formula (I)
- -
-
-
- SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS
-
The present invention relates to a process for the preparation substantially pure propane-1-sulfonicacid-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide or Vemurafenib of Formula (I). The present invention further relates to a process for the preparation substantially pure propane-1-sulfonic acid-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3 -b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide trifluoro methane sulfonic acid salt or Vemurafenib triflate of Formula (VII)
- -
-
Paragraph 0126-0127
(2018/12/04)
-
- SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS
-
The present Invention relates to a process for the preparation substantially pure propane- 1 -sulfonicacid- { 3 -[5 -(4-chiorophenyI)-1 H-pyrrolo [2,3-b]pyridine-3 -carbonyl]-2,4-difluoro-phenyl} -amide or Vemurafenib of Formula (1), The present invention further relates to a process for the preparation substantially pure propane- 1 -sulfonic acid- { 3 - [5-(4-chlorophenyi)-1H-pyrrolo [2,3-b]pyridine-3 -carbonyl] -2,4-difluoro-phenyl} -amide trifluoro methane sulfonic acid salt or Vemurafenib triflate of Formula (VII).
- -
-
Page/Page column 24
(2016/06/14)
-
- CRYSTALLINE FORMS OF VEMURAFENIB
-
The invention relates to new crystalline forms of vemurafenib, i.e. N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide of formula (I), exhibiting the following characteristic reflections in the X-ray powder pattern, measured with the use of CuKa radiation at the wavelength λ = 0.1542 nm: 6.5; 9.7; 18.0; 19.5 and 23,7 ± 0.2° 2-theta, and a method for the preparation thereof.
- -
-
Page/Page column 6
(2015/06/11)
-
- NOVEL PROCESSES FOR THE PREPARATION OF VEMURAFENIB
-
The present invention provides novel intermediates of vemurafenib or a pharmaceutically acceptable salt thereof and processes for its preparation. The present invention also provides novel processes for preparation of vemurafenib or a pharmaceutically acceptable salt thereof using the novel intermediates.
- -
-
-
- SOLID STATE FORMS OF VEMURAFENIB HYDROCHLORIDE
-
Provided herein are solid state forms of Vemurafenib hydrochloride, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising said solid state forms.
- -
-
-
- SYNTHESIS OF PYRROLO [2, 3 - B] PYRIDINES
-
Provided herein are intermediates and processes useful for facile synthesis of biologically active molecules.
- -
-
-
- Novel Processes for the manufacture of Propane-1-sulfonic acid -amide
-
According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as intermediates and novel synthesis routes for key intermediates used in those processes.
- -
-
-
- NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}-AMIDE
-
According to the present invention there are provided novel processes for the manufacture of the compound of formula (1) as well as novel synthesis routes for key intermediates used in those processes.
- -
-
-
- Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research
-
We report dramatically improved total syntheses of two highly selective V600EBRAF inhibitors, PLX4720 and PLX4032, that leverages microwave-assisted organic synthesis (MAOS). Compared with previously reported approaches, our novel MAOS method significantly reduces overall reaction time without compromising yield. In addition to providing a gram-scale route to these compounds for preclinical oncology research, we anticipate this approach could accelerate the synthesis of azaindoles in high-throughput, library-based formats.
- Buck, Jason R.,Saleh, Sam,Imam Uddin, Md.,Manning, H. Charles
-
p. 4161 - 4165
(2012/08/29)
-
- PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS
-
According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as novel synthesis routes for key intermediates used in those processes.
- -
-
Page/Page column 10
(2011/02/25)
-
- PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
-
Compounds of formula III which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
- -
-
Page/Page column 210-211
(2010/11/25)
-
